PRINCETON, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Cytogen Corporation , a product-driven, oncology-focused biopharmaceutical company, today announced that it would report 2005 fourth quarter and full year financial results on Thursday, February 23, 2006. The announcement will be followed by a conference call with the investment community at 9:00 a.m. EST.
Participating in the call from Cytogen will be Michael D. Becker, President and Chief Executive Officer, and other members of Cytogen’s senior management.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call is expected to last approximately one hour.
The schedule for the press release and conference call are as follows: -- Q4/2005 Press Release: February 23, 2006 at 7:00 a.m. EST -- Q4/2005 Conference Call: February 23, 2006 at 9:00 a.m. EST -- Domestic Dial-In Number: 866-383-8008, code 86406174 -- International Dial-In Number: 617-597-5341, code 86406174
This event can be accessed by going to the Company’s website at http://www.cytogen.com under its “Investor Relations” section. A direct link to the webcast is under the “Calendar of Events” header. The event will be archived and available for replay starting approximately one hour after the call and continuing for 7 days thereafter. The replay dial-in number for the U.S. is 888-286-8010 and the dial-in number for international callers is 617-801-6888. The replay pass code number is 30145799.
About Cytogen Corporation
Founded in 1980, Cytogen Corporation of Princeton, NJ is a biopharmaceutical company that acquires, develops and commercializes innovative molecules targeting the sites and stages of cancer progression. Cytogen’s marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide in the United States. Cytogen also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Cytogen’s development pipeline consists of therapeutics targeting prostate- specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Full prescribing information for the Company’s products is available at http://www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company’s website at http://www.cytogen.com, which is not part of this press release.
This press release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen’s results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen’s business is subject to a number of significant risks, which include, but are not limited to: the risk of obtaining additional capital; the risk of obtaining the necessary regulatory approvals; the risk of whether products result from development activities; the risk of shifts in the regulatory environment affecting sales of Cytogen’s products such as third-party payor reimbursement issues; the risk associated with Cytogen’s dependence on its partners for development of certain projects, as well as other factors expressed from time to time in Cytogen’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with Cytogen’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Cytogen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Cytogen Corporation
CONTACT: Media/Investors contact: Jonathan Fassberg, The Trout Group,+1-212-477-9007 x16, for Cytogen Corporation
Web site: http://www.cytogen.com/
